BIIB - XBI: Biotech Performance And Valuation Update - June 2019

SPDR Biotech ETF (NYSE:XBI) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskiest of stocks to invest while also offering the potential for outsized returns. Biotech has been exceptionally volatile over the past year weighed down by poor sentiment from decelerating growth among the mega-cap firms in the group among broader macro themes. This article highlights the performance of XBI underlying stocks including